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Abstract
Hypoxic-ischemic encephalopathy (HIE) in preterm infants is a severe disease for which no curative treatment is
available. Cerebral inflammation and invasion of activated peripheral immune cells have been shown to play a pivotal
role in the etiology of white matter injury, which is the clinical hallmark of HIE in preterm infants. The objective of this
study was to assess the neuroprotective and anti-inflammatory effects of intravenously delivered mesenchymal stem
cells (MSC) in an ovine model of HIE. In this translational animal model, global hypoxia-ischemia (HI) was induced in
instrumented preterm sheep by transient umbilical cord occlusion, which closely mimics the clinical insult.
Intravenous administration of 2 x 106 MSC/kg reduced microglial proliferation, diminished loss of oligodendrocytes
and reduced demyelination, as determined by histology and Diffusion Tensor Imaging (DTI), in the preterm brain after
global HI. These anti-inflammatory and neuroprotective effects of MSC were paralleled by reduced electrographic
seizure activity in the ischemic preterm brain. Furthermore, we showed that MSC induced persistent peripheral T-cell
tolerance in vivo and reduced invasion of T-cells into the preterm brain following global HI. These findings show in a
preclinical animal model that intravenously administered MSC reduced cerebral inflammation, protected against white
matter injury and established functional improvement in the preterm brain following global HI. Moreover, we provide
evidence that induction of T-cell tolerance by MSC might play an important role in the neuroprotective effects of MSC
in HIE. This is the first study to describe a marked neuroprotective effect of MSC in a translational animal model of
HIE.
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Introduction
Preterm infants are prone to brain injury after a perinatal
hypoxic-ischemic insult [1–3]. Hypoxic-ischemic
encephalopathy (HIE) in preterm infants is predominantly
characterized by white matter injury (i.e. periventricular
leukomalacia) which is caused by damage to highly vulnerable
immature oligodendrocytes [1,2,4]. HIE in preterm infants is
associated with cognitive disorders in 25-50% of all cases and
5-10% suffer from severe motor deficits (i.e. cerebral palsy) [5].
However, therapeutic options to improve the
neurodevelopmental outcome in preterm infants after HIE are
unavailable.
There is mounting evidence that the inflammatory response
following brain ischemia plays a crucial role in the
pathophysiology of ischemic brain injury [6,7]. This concept is
predominantly based on literature showing activation of the
cerebral and peripheral immune system after focal ischemia
(i.e. stroke; transient or permanent occlusion of cerebral
perfusion) in adult [8,9] and term neonatal [10] rodent models.
Recently, we have demonstrated in a translational ovine model,
that global hypoxia-ischemia (HI), which was induced by
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transient umbilical cord occlusion, caused cerebral
inflammation and activation of the peripheral immune system in
a similar way as observed after focal ischemia [11]. More
precisely, we showed in this model, which is representative for
brain development of preterm infants, that global HI induced a
profound microglial response followed by a second peripheral
inflammatory response characterized by invasion of mobilized
peripheral immune cells into the ischemic preterm ovine brain
[11]. These inflammatory changes were associated with
marked injury to pre-oligodendrocytes and hypomyelination of
the preterm brain [11], which are well known indicators of white
matter injury in the ischemic preterm brain [1,2,12]. Our
findings indicated that the immature immune system is readily
mobilized after global HI and is involved in the etiology of white
matter injury, the clinical hallmark of hypoxic-ischemic preterm
brain injury [11].
Since inflammation plays an important role in the etiology of
neonatal brain injury, neuroprotective therapies should have
strong anti-inflammatory and regenerative capacities if aimed
at the repair of the hypoxic-ischemic neonatal brain.
Mesenchymal stem cells (MSC) meet these criteria [13–16],
and therefore several studies have been conducted to assess
whether MSC therapy can protect the neonatal term brain after
focal ischemia [17–22]. The objective of our study was to
assess the neuroprotective and anti-inflammatory potential of
MSC therapy in the preterm brain exposed to global hypoxic-
ischemia. We hypothesized that intravenously administered
human bone-marrow derived MSC would be neuroprotective in
a translational animal model of preterm HIE. To test this
hypothesis, preterm instrumented sheep were exposed to 25
minutes of umbilical cord occlusion at 0.7 gestation. At this time
of gestation neurodevelopment of fetal sheep is equivalent to
that of a preterm infant of 30-32 weeks [23,24]. The
neuroprotective effect of MSC treatment was studied by
assessment of white matter injury and electrographic seizure
activity. The anti-inflammatory effect of MSC treatment was
studied by evaluation of the peripheral T-cell response.
Materials and Methods
Ethics Statement
The experimental protocol and design of the study were in
line with the institutional guidelines for animal experiments and
were approved by the institutional Animal Ethics Research
committee of Maastricht University, The Netherlands.
Animals and surgery
Fetuses of time-mated Texel ewes were instrumented as
previously described [11]. In short, all fetuses were
instrumented with an arterial catheter for blood pressure
measurements and blood sampling, a venous catheter for
administration of MSC and ECG electrodes for heart rate
monitoring. EEG electrodes were placed as previously
described [11]. The anterior and posterior placed electrodes
were considered C3–C4 channel and P3–P4 channel,
respectively. An inflatable vascular occluder (OC16HD, 16mm,
In Vivo Metric, Healdsburg, CA, USA) was placed around the
umbilical cord to induce transient global HI. All fetal catheters
and leads were exteriorized through a trocar hole in the flank of
the ewe. The welfare of the animals was monitored daily by
certified personnel.
Randomization and blinding
Prior to the entire series of experiments, animals were
randomized by an independent researcher who was not
involved in the animal experiments. The randomization resulted
in four experimental groups (Figure 1). The investigator
performing the (sham) umbilical cord occlusions was blinded
for treatment allocation. Tissue sampling and the analyses of
brain tissue and electrophysiological data were conducted in a
blinded fashion.
Experimental design
Fetuses were instrumented at 101.5 ± 1.0 (mean ± SD) days
of gestation (experimental day -4). After surgery ewe and fetus
were allowed to recover for four days. At gestational age 105.5
± 1.1 (mean ± SD) (experimental day 0) fetuses were subjected
to 25 minutes of umbilical cord occlusion (Figure 2) by rapidly
inflating the occluder. After umbilical cord occlusion a
reperfusion period of 7 d followed.
Mesenchymal stem cells
Human bone marrow-derived mesenchymal stem cells
(Merck Millipore, Billerica MA, USA) isolated from a male
healthy donor were expanded following the manufacturer’s
protocol. After four passages the cells were frozen in freezing
medium containing 10% FCS and 10% DMSO and stored in
liquid nitrogen. The expanded MSC were validated for their
differentiation potential and cell surface molecules. MSC
effectively differentiated into osteoblasts and adipocytes (data
not shown). Expression of cell surface molecules on infused
MSC was confirmed by flow cytometry analysis. MSC
expressed CD44, HLA-I, CD49c, CD13, CD54, CD58, CD140b,
CD105, CD90, CD73 dimly expressed CD117 and CD49d and
did not express HLA-II, CD45, CD34, CD40, CD80, CD146,
CD3, CD86 and CD19.
MSC were thawed and washed twice with PBS one hour
before administration. MSC were infused intravenously 1 h
after (sham) umbilical cord occlusion. Fetuses received 3.5 x
106 MSC (approximately 2.0 x 106/kg BW) resuspended in 1
mL PBS via the venous line.
Data acquisition
Physiological data was acquired as described previously
[11]. After filtering, the raw EEG signals of the central and
posterior channels were converted into amplitude-integrated
EEG (aEEG) traces, using a Matlab® (R2011b; The Mathworks
Inc., Natick, MA, USA) algorithm similar to the clinical EEG
NicoletOneTM device (Viasys Healthcare, Conshohocken, PA,
USA) [25]. The EEG processing included an asymmetric band-
pass filter that strongly attenuates activity below 2 Hz and
above 15 Hz, semi-logarithmic amplitude compression and
time compression [26]. The (a) EEG traces were used to detect
electrographic seizure activity, which in the aEEG usually is
seen as an abrupt rise in the lower margin amplitude (LMA)
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and a simultaneous rise in the upper margin amplitude (UMA),
often followed by a short period of decreased amplitude [27].
The raw EEG simultaneously shows gradual build-up and
decline in amplitude of repetitive sharp-waves [28]. From 24 h
before UCO to the end of the experiment, aEEG and EEG were
displayed simultaneously. Electrographic seizure activity with a
duration ≥ 10 s was annotated using both aEEG/EEG traces in
n=6 animals per experimental group. Annotation was
performed by a neonatologist, experienced in neonatal aEEG
interpretation, who was blinded for treatment allocation.
MRI
At the end of the experiment (day 7), the fetal brain was
removed from the skull and weighed. The right hemisphere
was submersion fixated in 4% paraformaldehyde (PFA) for 3
months and stored at 4 degrees Celsius. Forty eight hours prior
to MRI imaging, the right hemisphere was washed with PBS
and stored in PBS containing 1% sodiumazide at 4 degrees
Celsius to wash out all PFA. After optimization, all DTI images
were acquired using an echo planar imaging (EPI) sequence
with diffusion gradients (b=4000 s/mm2) applied in 66 non-
collinear directions and 6 B0 measurements. An average of 60
slices was recorded within 36 minutes using a repetition time
(TR) = 500 ms and echo time (TE) = 75 ms. Isovolumetric
voxel size was 0.5 mm3. The FOV was 30x60x60 mm and scan
matrix size 60x120x60 mm.
DTI data was post processed using ExploreDTI software and
fractional anisotropy (FA) maps maps were displayed [29].
White matter injury was assessed by measuring fractional
anisotropy (FA), which has been previously shown to be
unaffected by fixation [30]. Delineation of ROIs was performed
by a neonatologist, experienced in DTI analysis, who was
blinded for the treatment allocation. FA values within the
delineated ROI in the SCWM and hippocampus were
calculated with ExploreDTI [29].
Immunohistochemistry brain
Following MRI imaging the right hemisphere was embedded
in gelatin and serial coronal sections (50 µm) were cut on a
Leica VT 1200S vibrating microtome (Leica Biosystems,
Nussloch, Germany). Free floating sections at the level of mid-
thalamus and posterior hippocampus were stained with a rabbit
anti-ionized calcium binding adaptor molecule 1 (IBA-1)
antibody (Wako Pure Chemical Industries, Osaka, Japan),
which is a highly specific marker for microglia, localizing resting
and activated microglia [11]. A mouse anti-O4 antibody (Merck
Millipore, Billerica, MA, USA) was used to detect pre-
oligodendrocytes (preOLs) (oligodendrocyte progenitors and
immature oligodendrocytes) and a rat anti-myelin basic protein
(MBP) antibody (Merck Millipore, Billerica, MA, USA) was used
to detect myelin sheaths and myelin producing (mature)
oligodendrocytes. Endogenous peroxidase-activity was blocked
by incubation with 0,3% H2O2 in Tris buffered saline (TBS, pH
7.6). Free floating sections were incubated overnight (anti-
IBA-1 and MBP) or during three days (anti-O4) at 4°C with the
diluted primary antibody (1:1000 anti-IBA-1, 1:400 anti-O4 and
1: 2000 MBP) followed by incubation with a secondary donkey-
anti-rabbit (anti-IBA-1), donkey-anti-rat (MBP) or donkey-anti-
Figure 1.  Study design.  Fetuses were instrumented at a gestational age (GA) of 102 d. After a recovery period of 4 d fetuses
were subjected to 25 min of umbilical cord occlusion (UCO) or sham. One hour after UCO or sham, fetuses received either
intravenous mesenchymal stem cells (2.0 million/kg BW) (closed arrow) or saline 0,9% (open arrow). After a 7 d reperfusion period
brain tissue was collected. Abbreviations: in = instrumentation, HI = hypoxia-ischemia, SAL = saline, MSC = mesenchymal stem
cells.
doi: 10.1371/journal.pone.0073031.g001
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mouse (anti-O4) biotin labeled antibody. The immunostaining
was enhanced with Vectastain ABC peroxidase Elite kit
(PK-6200, Vector Laboratories, Burlingame, CA, USA) followed
by a nickel sulfate-diaminobenzidine (NiDAB) staining.
Sections were mounted on gelatin-coated glass slides, air-
dried, dehydrated in ascending ethanol concentrations and
coverslipped with PerTex.
After cutting of free floating sections, the remainder of the
tissue was embedded in paraffin and serial coronal sections (4
µm) were cut. Sections at the level of mid-thalamus and
posterior hippocampus were stained with CD3 (DAKO A0452,
DAKO, Denmark) for detection of T-cells. Endogenous
peroxidase was inactivated by incubation with 0,3% H2O2 that
was dissolved in PBS. Antigen retrieval was performed by
boiling in citrate buffer pH 6.0. Antigen aspecific binding was
prevented by incubating the slides for 30 minutes with 5%
bovine serum albumin (BSA). Slides were incubated overnight
at 4°C with the diluted primary antibody (CD3 1:200) followed
by incubation with the appropriate secondary biotin labeled
antibody. Immunostaining was enhanced with Vectastain ABC
peroxidase Elite kit (PK-6200, Vector Laboratories) followed by
Figure 2.  Reproducibility of 25 min umbilical cord occlusion (UCO).  (A) Fetal mean arterial blood pressure (MABP) and (B)
fetal heart rate (FHR) measurements indicated that all animals exposed to global HI experienced the same degree of hypotension
and bradycardia, respectively, at the end of UCO; means (thick line) ± SD (shaded areas) of n=8 animals per experimental group
are shown. MABP and FHR normalized within one hour after the end of UCO and were stable throughout the rest of the study
period. All sham operated animals had similar MABP and FHR parameters during the entire duration of the study. For clarity
reasons the sham-SAL and sham-MSC groups are depicted as one sham group. (C–E) Blood gas analysis indicated that twenty five
minutes of umbilical cord occlusion induced comparable acidosis, hypoxemia and hypercarboxemia in all animals exposed to global
HI, as demonstrated by (C) arterial pH, (D) arterial partial oxygen pressure (pO2) and (E) arterial partial carbon dioxide pressure
(pCO2), respectively; means (lines) ± SD (error bars) of n=8 animals are depicted. Blood gas indices in animals exposed to global HI
normalized within one hour after the end of UCO and stayed within the normal range throughout the rest of the study period.
doi: 10.1371/journal.pone.0073031.g002
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a NiDAB staining. Sections were counterstained with 0.1%
Nuclear Fast Red washed, dehydrated and coverslipped.
Analysis of immunohistochemistry
For the analysis of IBA-1 immunoreactivity, digital images of
the subcortical white matter (SCWM) (100x magnification) and
hippocampus (20x magnification) were acquired using an
Olympus AX-70 microscope (Olympus, Tokyo, Japan)
equipped with a black and white digital camera. For the
analysis of IBA-1 immunoreactivity, n=6 for sham-SAL, n=3 for
sham-MSC, n=6 for HI-SAL and n=6 for HI-MSC animals per
group were analyzed. In each individual animal, IBA-1
immunoreactivity was assessed in six consecutive coronal
sections (posterior hippocampus/ mid-thalamus level). In the
hippocampus, area fraction of IBA-1 immunoreactivity was
assessed in one 20x digital image per section by delineating
the hippocampus and determining the areal fraction of IBA-1
immunoreactivity expressed as a percentage of total
hippocampal area with a standard threshold using Leica Qwin
Pro V 3.5.1 software (Leica, Rijswijk, the Netherlands). In the
SCWM, the area fraction of IBA-1 immunoreactivity was
determined in five adjacent 100x digital images obtained in
standardized locations within the SCWM of each section
(Figure 3A). The results of five images per section were
averaged to obtain the areal fraction of IBA-1 immunoreactivity
within the SCWM for each section. The digital images were
obtained and analyzed by an independent observer who was
blinded to the experimental conditions.
For the analysis of MBP immunoreactivity, digital images of
the subcortical white matter (SCWM) (100x magnification) were
acquired using the Olympus AX-70 microscope. For the
analysis of MBP immunoreactivity, n=6 for sham-SAL, n=3 for
sham-MSC, n=6 for HI-SAL and n=6 for HI-MSC animals per
group were analyzed. In each individual animal, MBP
immunoreactivity was assessed in six consecutive coronal
sections (posterior hippocampus/ mid-thalamus level). In the
SCWM, the MBP immunoreactivity was determined in five
adjacent 100x digital images obtained in standardized locations
within the SCWM of each section (Figure 3A). Areal fraction of
MBP-positive myelin sheaths was determined in each digital
image with a standard low-pass intensity threshold set to detect
all MBP immunoreactivity and a standard high-pass intensity
threshold set to exclude the intense staining of the MBP-
positive mature oligodendrocytes (Figure 4B) using Leica Qwin
Pro V 3.5.1 software. By excluding the immunoreactivity of
MBP-positive mature oligodendrocytes the measurements
accurately represented white matter only. The results of five
images per section were averaged to obtain the areal fraction
of MBP immunoreactivity within the SCWM for each section.
The digital images were obtained and analyzed by an
independent observer who was blinded to the experimental
conditions.
O4 immunoreactivity in the SCWM was assessed as
previously described [11]. In short, a differential count was
performed, discriminating between immature (ring-shaped
membrane staining, no processes), mature (ring-shaped
membrane staining, extensively branched processes) and
degenerative (fragmented membrane staining, fragmentation of
processes, signs of cell death; nuclear condensation and
apoptotic bodies) phenotype of the O4 positive cells. The sum
of the differential count resulted in the total number of O4
positive cells. For the analysis of O4 positive cells in the
SCWM, n=6 for sham-SAL, n=3 for sham-MSC, n=6 for HI-SAL
and n=6 for HI-MSC animals per group were analyzed. In each
individual animal, the number of O4 positive cells was
assessed in six consecutive coronal sections (posterior
hippocampus/ mid-thalamus level). In each section, O4 positive
cells were counted in eight randomly chosen fields of view in
the SCWM (within the regions as indicated in Figure 3A) with a
40x objective equipped with a counting grid (0.0625 mm2) using
a Nikon Eclipse E400 microscope (Nikon, Amsterdam, the
Netherlands). The results of the eight differential counts were
averaged to obtain the differential count of O4 positive cells per
section. The investigator who performed the differential count
was blinded to the experimental conditions.
For the analysis of CD3 staining in the SCWM, three coronal
sections per animal (n=4 for sham-SAL, n=4 for sham-MSC,
n=4 for HI-SAL and n=4 for HI-MSC) were studied at the
posterior hippocampus/ mid-thalamus level. In each section,
cells were counted in ten fields of view (focused on the cerebral
vasculature) in the subcortical white matter with a 20x objective
equipped with a counting grid (0.25 mm2) using a Nikon Eclipse
E400 microscope (Nikon, Amsterdam, the Netherlands). The
numbers of CD3-positive cells were expressed as cells per field
of view (FOV).
Proliferation assay
At the end of the experiment (day 7), the spleen was
immediately harvested after sacrifice. Single-cell splenocyte
suspensions were obtained by dissociating freshly sampled
spleen tissues in gentleMACS™ C-tubes (MiltEnyi, Leiden, the
Netherlands) filled with Gibco® Iscove’s Modified Dulbecco’s
Medium (IMDM) (Life Technologies, Bleiswijk, the Netherlands)
using the gentleMACS™ Dissociator (MiltEnyi, Leiden, the
Netherlands). Subsequently, the cell suspensions were passed
through a 70 µm cell strainer (BD Biosciences, Erembodegem-
Aalst, Belgium). Splenocytes were stored in nitrogen in freezing
medium containing IMDM medium with 10% heat-inactivated
FCS and 10% DMSO.
For the proliferation assay, splenocytes of all experimental
groups (sham-SAL n=4, sham-MSC n=4, HI-SAL n=4, HI-MSC
n=4) were thawed. Splenocytes were labeled with CFSE
(Sigma-Aldrich, Zwijndrecht, The Netherlands) in a final
concentration of 1 µM. CFSE-labeled splenocytes were plated
at a concentration of 1.0 million cells/mL in a round bottom 96-
wells plate in DMEM (Gibco®, Life Technologies, Bleiswijk, The
Netherlands) culture medium containing 10% FCS and 1%
Penicillin Streptomycin solution. CFSE-labeled splenocytes
were stimulated by adding Phytohemagglutinin (PHA) (Lectin;
Sigma-Aldrich, Zwijndrecht, The Netherlands) at a final
concentration of 1 µg/mL and human recombinant IL-2
(Proleukin®; Aldesleukin (Chiron), Novartis, Basel,
Switzerland) at a final concentration of 500 IU/mL to the culture
medium. These final concentrations yielded optimal
proliferation of fetal sheep splenocytes in pilot experiments
(data not shown). Stimulated splenocytes were cultured during
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five days in an incubator set at 37°C and 5% CO2. On day 5 the
proliferated splenocytes were stained for detection of T-helper
cells (mouse anti sheep CD4-AlexaFluor® 647 (CD4-A647);
AbDSerotec, Düsseldorf, Germany), cytotoxic T-cells (mouse
anti sheep CD8-R-PE (CD8-PE); AbDSerotec, Düsseldorf,
Germany) and viability (7-Aminoactinomycin D (7-AAD); BD
Biosciences, Bleiswijk, the Netherlands) according to the
manufacturer’s protocol. Stained cells were acquired on a
FACS Canto II flow cytometer (BD Biosciences, Bleiswijk, the
Netherlands) equipped with FACS Diva software (BD
Biosciencs, Bleiswijk, the Netherlands). Gating strategy is
depicted in Figure S1A–C. The number of non-proliferating
(high CFSE fluorescent intensity) CD4- and CD8-positive cells
was expressed as a percentage of total viable splenocytes in
the well.
Because of the lack of good flow cytometry antibodies cross-
reacting with ovine lineage markers it was not possible to gate
on CD3. However, it was possible to discriminate between
ovine CD4-positive T-cells and CD8-positive T-cells (gating
strategy; Figure S1). Cells being positive for both CD4 and
Figure 3.  Intravenous MSC reduced proliferation of microglia after global HI.  (A) Immunohistochemical IBA-1 staining in the
SCWM of the four experimental groups with squares in the first panel indicating the regions where immunoreactivity was assessed.
Global HI induced a profound increase of IBA-1 immunoreactivity, which was significantly reduced by intravenous MSC treatment.
(B) Immunohistochemical IBA-1 staining in the hippocampus of the four experimental groups. Profound proliferation of microglia
was observed in the hippocampus following global HI. MSC partially reduced the inflammatory response of microglia in the
hippocampus after global HI. (C–D) Graphical presentation of area fraction of IBA-1 immunoreactivity in SCWM and hippocampus;
(C) geometric means ± 95% CI and (D) means ± 95% CI and levels of significance are depicted, which were calculated by the
random intercept model with all repeated measures (i.e. brain sections) per animal (sham-SAL n=6, sham-MSC n=3, HI-SAL n=6,
HI-MSC n=6). Dots show the averaged results of the repeated measures (i.e. brain sections) per animal. * P≤0.05, ‡ P≤0.01, #
P≤0.001. IBA-1 = ionized calcium binding adaptor molecule 1, HI = hypoxia-ischemia, SAL = saline, MSC = mesenchymal stem
cells, IR = immunoreactivity. (A–B) Scale bars represent 1 mm.
doi: 10.1371/journal.pone.0073031.g003
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CD8 are presumably monocytes or myeloid cells (with Fc
receptor) and were not taken along in our analysis. The gate
for the non-proliferating fraction was set based on the condition
without mitogen (data not shown).
Fluorescent In Situ Hybridization (FISH)
The FISH probe for chromosomes Y (DYZ3, Sat. III) [31] was
selected to identify intravenously administered human male
MSC in the preterm ovine brain. The probe was labeled by
standard nick translation with biotin (Bio). The labeled probe
was applied at a concentration of 1 ng/µl in 60% formamide, 2x
SSC, 10% dextran sulphate, and a 50x excess of carrier DNA
(salmon sperm DNA). FISH was performed on 4 µm thick
formalin fixed and paraffin embedded tissue sections (at the
posterior hippocampus/ midthalamus level) put on amino
coated slides (superfrost plus+). In brief, sections were heated
at 80 °C for 15 minutes to improve cellular adhesion to the
slides during the entire FISH procedure, dewaxed and hydrated
Figure 4.  Intravenous MSC treatment reduced loss of pre-oligodendrocytes and demyelination after global HI.  (A)
Immunohistochemical O4 staining in the subcortical white matter (SCWM) of all four experimental groups. The number of O4-
positive cells was similar between sham operated animals treated with saline or MSC. Global HI induced marked loss of O4-positive
cells. Intravenous MSC significantly increased the number of O4-positive cells after global HI. (B) Immunohistochemical MBP
staining in the SCWM of all four experimental groups. The area fraction of MBP was similar between sham operated animals treated
with saline or MSC. Marked hypomyelination was observed in the SCWM following global HI. Intravenous MSC significantly
increased myelination of the preterm brain after global HI. (C–D) Graphical presentation of number of O4-positive cells and MBP
immunoreactivity in SCWM; (C) means ± 95% CI (D) geometric means ± 95% CI and levels of significance are depicted, which were
calculated by the random intercept model with all repeated measures (i.e. brain sections) per animal (sham-SAL n=6, sham-MSC
n=3, HI-SAL n=6, HI-MSC n=6). Dots show the averaged results of the repeated measures (i.e. brain sections) per animal. * P≤0.05,
‡ P≤0.01, # P≤0.001. PreOL = pre-oligodendrocytes, HI = hypoxia-ischemia, SAL = saline, MSC = mesenchymal stem cells, IR =
immunoreactivity, log = natural logarithm. Scale bars: (A) 100 µm, (B) 200 µm.
doi: 10.1371/journal.pone.0073031.g004
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followed by microwaving in 10 mM Na-Citrate pH buffer 1 x 10
min at 100 °C and 20 min at RT to cool down. Washed in
demineralized water and rinsed in 0.01 M HCl and
subsequently digested in 2.5 mg pepsin in 0.01 N HCl.
Afterwards the slides were washed in 1 x 0.01 N HCl, 1 x PBS
and post fixed in 1% formaldehyde in PBS for 5 min at RT.
Slides were washed with PBS, demineralized water and
dehydrated in an alcohol series. The probe was applied under
a coverslip, simultaneously denatured at 80 °C for 10 min and
hybridized overnight at 37 °C. After hybridization, the
preparations were washed for 5 min in 2 x SSC, 0.05%
tween-20 (Janssen Chimica, Beerse, Belgium) and 0.1 X SSC
61 °C (2 × 5 min). The hybridized probe was detected in a triple
layer detection method with FITC-conjugated avidin (Av-FITC,
1: 100 dilution; Vector Laboratories, CA, USA), biotinylated
goat anti-avidin (Bio-GaA, 1:100 dilution: Vector Laboratories)
and Av-FITC. Finally, the slides were washed in PBS
containing 0.05% Tween-20, dehydrated in an ascending
ethanol series, and mounted in Vectashield (Vector
Laboratories) containing DAPI (Sigma: 0.5 µg/µl). Images were
recorded with the Metasystems Image Pro System (black and
white CCD camera; Sandhausen, Germany) mounted on top of
a Leica DM-RE fluorescence microscope equipped with FITC
and DAPI single band pass filters for single color analysis.
Images were recorded using an automatic integration time
allowing semi quantitative evaluation (using the full dynamic
range of the camera without signal intensity saturation; TIF 8
bits image).
PCR
The distribution of MSC throughout the tissues was
confirmed by PCR for human-specific β-2 microglobulin as
previously reported [32]. Genomic DNA that was used as
template was extracted from snap frozen tissues including
subcortical white matter and hippocampus of the left
hemisphere, fetal lung (right middle lobe) and spleen using the
Wizard Genomic Purification kit (Promega, Leiden, The
Netherlands) according to the supplier’s recommendations.
The presence of amplifiable DNA was evaluated by PCR for β-
actin. PCR reactions were performed in a total volume of 25 µl
with specific primers for β-actin or β-2 microglobulin using 1 µl
of genomic DNA. Next, a nested PCR was conducted for β-2
microglobulin using 2.5 µl of the amplified product of the first
reaction as a template. The amplified products were separated
on ethidium bromide-stained 2% agarose gels and captured
using the Imagemaster® VDS equipped with a CCD camera
(GE Healthcare Life Sciences (Pharmacia Biotech), Uppsala,
Sweden). The amplified products were evaluated using the Big
Dye termination sequencing kit (PerkinElmer/Cetus, Emeryville,
CA).
Primers for β-actin were 5’-CGGGACCTGACTGACTAC-3’
(sense) and 5’-GAAGGAAGGCTGGAAGAG-3’ (antisense);
primers used for the amplification of β-2 microglobulin were 5’-
GTGTCTGGGTTTCATCAATC-3’ (sense), 5’-
GGCAGGCATACTCATCTTTT-3’ (antisense), 5’-
TGGGTTTCATCAATCCGACAT-3’ (nested sense) and 5’-
CTCATCTTTTTCAGTGGGGGT-3’ (nested antisense).
PCR were performed in a total volume of 25 µl in PCR buffer
(Promega, Leiden, The Netherlands) in the presence of 0.2 mM
dNTP (Promega, Leiden, The Netherlands), 1 M of each
primer, 0.3 mM MgCl2, and 0.5 U of Taq polymerase
(Promega, Leiden, The Netherlands). PCR conditions for each
primer couple were as follows: β-actin; 95°C for 30 s, 53°C for
45 s and 72°C for 30 s during 40 cycles: human-specific β-2
microglobulin; 95°C for 30 s, 53°C for 30 s and 72°C for 20 s
during 45 cycles: human-specific β-2 microglobulin nested
95°C for 30 s, 50°C for 45 s and 72°C for 20 s during 45 cycles.
Statistics
Summary statistics of animal characteristics and all outcome
parameters are shown as means with 95% CI. Groups’
comparisons with respect to all outcome parameters (except
seizure data) were drawn with analysis of variance (ANOVA) or
with random intercept models in case of repeated
measurements per animal (e.g. different sections per brain).
Since these tests assume normal distribution of the data,
variables, whose distributions were positively skewed, were
log-transformed previous to statistical testing. To facilitate
interpretation, averages on the log scale were back
transformed to the original scale (antilog) and are presented as
geometric means and corresponding 95% CIs, as previously
reported [11]. Seizure data was zero-inflated (i.e. no seizures in
sham animals), showing pronounced skewness that could not
be remedied by log transformation. Hence, pair-wise groups’
comparisons of seizure data were performed with
nonparametric Mann-Whitney tests. Seizure data are
presented as medians and corresponding interquartile range
(IQR). For assessment of correlations, the Pearson or
Spearman correlation coefficient was calculated, as
appropriate. To avoid overestimation of treatment effects, a
False Discovery Rate (FDR) of 5% was used for multiple
testing correction. Groups’ differences with FDR corrected
P<0.05 were considered statistically significant. Statistical
analysis was performed with IBM SPSS Statistics Version 20.0
(IBM Corp., Armonk, NY, USA).
Results
Animal characteristics and reproducibility of umbilical
cord occlusion
Fetal body weight and gestational age at the time of UCO did
not differ significantly between the four experimental groups
(Table 1). No differences were found in MABP, FHR, pH,
arterial partial oxygen pressure or arterial partial carbon dioxide
pressure between the HI-SAL and HI-MSC group, indicating
that the physiological response to UCO and the degree of
acidosis, hypoxemia and hypercarboxemia was similar in all
animals exposed to global HI (Figure 2).
MSC reduced microglial proliferation after global HI
Global HI resulted in a significant (sham-SAL vs. HI-SAL;
P=0.002) increase of IBA-1 immunoreactivity in the SCWM,
indicating profound microglial proliferation in this region (Figure
3 A and C). In line, significantly (sham-SAL vs. HI-SAL;
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P<0.001) increased IBA-1 immunoreactivity was found in the
hippocampus following global HI (Figure 3 B and D).
Intravenous MSC significantly (HI-SAL vs. HI-MSC; P=0.020)
reduced IBA-1 immunoreactivity in the SCWM (Figure 3 A and
C). Intravenous MSC administration partially reduced IBA-1
immunoreactivity in the hippocampus, but the difference did not
reach statistical significance (HI-SAL vs. HI-MSC; P=0.218)
(Figure 3 B and D).
MSC reduced white matter injury after global HI
The O4-positive preOLs observed in the SCWM were
predominantly of immature phenotype (i.e. ring-shaped
membrane staining, no processes) (Figure 4 A). The number of
O4-positive cells was significantly (sham-SAL vs. HI-SAL;
P<0.001) decreased after global HI in the SCWM (Figure 4 A
and C), indicating HI-induced loss of preOLs in this region.
Intravenous MSC administration significantly (HI-SAL vs. HI-
MSC; P=0.002) increased the number of O4-positive preOLs
with immature phenotype in the SCWM (Figure 4 A and C).
The number of preOL was inversely related (r = -.83, P<0.001)
to IBA-1 immunoreactivity in the SCWM (Figure S2 A).
Global HI significantly (sham-SAL vs. HI-SAL; P<0.001)
reduced MBP immunoreactivity in the SCWM, indicating
marked demyelination in this region (Figure 4 B and D).
Accordingly, the number of MBP-positive mature
oligodendrocytes clearly decreased following global HI (Figure
4 B). Intravenous MSC administration significantly increased
(HI-SAL vs. HI-MSC; P=0.007) myelination (Figure 4 B and D).
In line, loss of MBP-positive mature oligodendrocytes was
prevented by MSC treatment (Figure 4 B). MBP
immunoreactivity was inversely related (r = -.71, P=0.002) to
IBA-1 immunoreactivity in the SCWM (Figure S2 B).
FA values in the SCWM were significantly decreased (sham-
SAL vs. HI-SAL; P=0.017) following global HI (Figure 5 A and
B), indicating disturbed organization of white matter tracts.
Intravenous MSC administration significantly increased (HI-
SAL vs. HI-MSC; P=0.028) FA values in the SCWM following
global HI (Figure 5 B), indicating that intravenous MSC
prevented disturbances in white matter tracts organization. In
line with clinical findings [33], DTI did not show significant
Table 1. Animal characteristics.
 sham-SAL (n=8) sham-MSC (n=8) HI-SAL (n=8) HI-MSC (n=8)
 mean (95% CI) mean (95% CI) mean (95% CI) mean (95% CI)
GA at
UCO
(d)
105.5
(104.9;106.1)
105.3
(104.6;106.1)
105.3
(104.7;105.9)
105.8
(105.0;106.7)
BW
(g)
1791.9
(1602.2;1963.7)
1783.0
(1584.7;1981.3)
1742.0
(1553.8;1930.2)
1829.7
(1586.8;2072.6)
brain
(g) 29.9 (28.2;31.5) 29.0 (27.3;30.8) 24.7 (23.3;26.2) 27.5 (25.5;29.5)
Fetuses were subjected to umbilical cord occlusion at a comparable age. Fetal
body weight did not differ between experimental groups. Global HI caused
significant brain atrophy, which was prevented by intravenous MSC administration.
changes of FA values after global HI in the hippocampus (data
not shown).
MSC reduced the electrographic seizure burden
following global HI
Global HI significantly increased (sham-SAL vs. HI-SAL
p=0.008) the electrographic seizure activity following UCO
(Figure 5 C-D). In line with clinical [34] and experimental [35]
data, the seizure activity peaked in the first 24 h after UCO,
followed by a second smaller peak in the period between 24
and 48 h after UCO (data not shown). Intravenous MSC
administration significantly reduced (HI-SAL vs. HI-MSC
p=0.031) the number of electrographic seizures during the
study period after global HI (Figure 5 D). Seizure activity was
very rarely detected in sham animals treated with saline or
MSC (Figure 5 D). Neuronal injury was further demonstrated by
significant (sham-SAL vs. HI-SAL; P<0.001) brain atrophy
following global HI (Table 1), which was diminished (HI-SAL vs.
HI-MSC; P=0.058 and sham-MSC vs. HI-MSC; P=0.381) by
intravenous MSC treatment (Table 1).
MSC induced sustained T-cell tolerance
The percentage of non-proliferative (i.e. reduced CFSE
dilution) CD4-positive splenocytes derived from HI-SAL
animals was not significantly altered compared to those
splenocytes from sham-SAL animals (Figure 6 A and C),
indicating that global HI did not alter the proliferative capacity of
splenocytes. Remarkably, the percentage of non-proliferative
CD4-positive splenocytes derived from sham-MSC animals
was significantly (P=0.012) increased compared to the sham-
SAL group (Figure 6 A and C). In line, the percentage of non-
proliferative CD4-positive splenocytes derived from HI-MSC
animals was significantly (P=0.020) increased compared to the
HI-SAL group (Figure 6 A and C), indicating that intravenously
administered MSC persistently suppressed the in vivo
responsiveness of CD4-positive helper T cells in the spleen.
The proliferation capacity of CD8-positive splenocytes was not
affected by global HI or MSC (data not shown). MSC-mediated
suppression of helper T-cells in vivo was inversely related
(Pearson r = -.60, P=0.035) to proliferation of microglia in the
subcortical white matter (Figure S2 C).
MSC reduced T-cell invasion after global HI
In sham conditions, T-cells were predominantly detected in
the intravascular space of the preterm brain (Figure 6 B).
Global HI significantly increased (sham-SAL vs. HI-SAL;
P<0.001) the number T-cells in the SCWM (Figure 6 B and D).
In the hypoxic-ischemic preterm brain, T-cells were primarily
located in the perivascular and interstitial space, indicating HI-
induced invasion of T-cells into the preterm brain (Figure 6 B).
Remarkably, intravenous MSC administration significantly
reduced (HI-SAL vs. HI-MSC; P=0.028) the number of T-cells
in the SCWM following global HI (Figure 6 B and D), indicating
that intravenous MSC prevented invasion of T-cells into the
preterm brain.
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Detection of MSC in the preterm brain seven days after
administration
Within the subcortical white matter of MSC treated animals,
we localized 20-40 cells per section that stained positive for the
human specific Y-chromosome probe (Figure 7 C and D). MSC
were detected in 4 of 5 studied animals that received MSC.
The presence of MSC in the brain was confirmed by human-
specific β2-microglobulin PCR (Figure S3). The amplified PCR
products contained the correct human β2-microglobulin
sequences as evaluated by sequencing. In addition, MSC were
detected with PCR in SCWM, hippocampus, lung and spleen
(data not shown).
Figure 5.  Intravenous MSC treatment prevented white matter injury and reduced electrographic seizure activity after
global HI.  (A) Regions of interest; SCWM and hippocampus in FA map. FA values in the hippocampus were not altered by global
HI (data not shown). (B) Global HI caused a significant decrease in FA values in the SCWM, which was prevented by intravenous
MSC administration; means ± 95% CI and levels of significance are depicted, which were calculated with ANOVA (sham-SAL n=8,
sham-MSC n=4, HI-SAL n=8, HI-MSC n=8). Dots show each measurement (i.e. non-repeated measures) per animal. * P≤0.05, ‡
P≤0.01, # P≤0.001. FA = fractional anisotropy, SAL = saline, MSC = mesenchymal stem cells, HI = hypoxia-ischemia. (C)
Representative image of an aEEG trace from a HI-SAL animal. The two upper traces represent aEEG traces of the C3-C4 and P3-P4
channel, respectively. The aEEG signal is time-compressed, showing a 120-min period. The amplitude is displayed semi-
logarithmic, indicating a LMA of approximately 4-3 µV and UMA of approximately 10 µV. The arrows indicate seizure activity. The
two lower traces depict the corresponding EEG signal (30 s) of one electrographic seizure activity indicated by the diamond. (D)
Intravenous MSC administration significantly reduced electrographic seizure burden following global HI; medians ± IQR are depicted
(sham-SAL n=6, sham-MSC n=6, HI-SAL n=6, HI-MSC n=6). * P≤0.05, ‡ P≤0.01, # P≤0.001. SAL = saline, MSC = mesenchymal
stem cells, HI = hypoxia-ischemia.
doi: 10.1371/journal.pone.0073031.g005
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Discussion
Hypoxic-ischemic encephalopathy (HIE) in preterm infants is
associated with cognitive and motor disorders, for which there
is currently no therapeutic cure. The lack of feasible
experimental models which are comparable to human
neurodevelopment is one of the main hurdles that prevent the
development of novel therapeutic strategies for hypoxic-
ischemic injury in the preterm brain. We and others previously
demonstrated that the fetal ovine model of global hypoxia-
ischemia (HI) by umbilical cord occlusion (UCO) closely
resembles the situation in human preterm infants in terms of
Figure 6.  Intravenous MSC modulated the peripheral T-cell response after global HI.  MSC persistently suppressed the
proliferative capacity of CD4-positive splenocytes and reduced the number of invading T-cells into the preterm brain follow global HI
and. (A) Representative flow cytometry histograms showing proliferation (increased CFSE dilution) of CD4-positive splenocytes
(green) and CD8-positive splenocytes (blue) derived from the different experimental groups. Global HI did not alter the proliferative
capacity of CD4-positive splenocytes (HI-SAL versus sham-SAL). MSC significantly suppressed the proliferation of CD4-positive
splenocytes in sham operated animals (sham-MSC versus sham-SAL) and in animals exposed to global HI (HI-MSC versus HI-
SAL). (B) Immunohistochemical CD3 (T-cell) staining in the subcortical white matter (SCWM) of all four experimental groups. In
sham conditions, T-cells were primarily detected in the intravascular space (open arrows). Following global HI, a significant increase
in the number of perivascular and interstitial (black arrows) CD3-positive cells was observed. T-cell invasion after global HI was
significantly reduced by MSC. (C–D) Graphical presentation of (C) the percentage of non-proliferative CD4-positive splenocytes and
(D) number of CD3-positive cells in SCWM; (C) means ± 95% CI and (D) geometric means ± 95% CI and levels of significance are
depicted, which were calculated by ANOVA for CD4 proliferation (C) and the random intercept model with all repeated measures
(i.e. brain sections) for CD3 counts (D). Dots show each measurement (i.e. non-repeated measures) per animal for CD4
proliferation (C) and the averaged results of the repeated measures (i.e. brain sections) per animal for CD3 counts (D). * P≤0.05, ‡
P≤0.01, # P≤0.001. SAL = saline, MSC = mesenchymal stem cells, HI = hypoxia-ischemia, FOV = field of view.
doi: 10.1371/journal.pone.0073031.g006
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neurodevelopment and white matter injury, which is the clinical
hallmark of hypoxic-ischemic injury in the preterm brain
[1,11,12]. In the current study, we use this translational animal
model to provide evidence for the therapeutic potential of
intravenous administration of MSC in the preterm brain after
global HI.
We first assessed the effects on the cerebral anti-
inflammatory effects of MSC by studying the proliferative
response of microglia, which are typically activated early after
global HI [11,36]. Our findings demonstrated that intravenous
administration of MSC reduced the cerebral inflammatory
response in the hypoxic-ischemic preterm brain after global HI.
Secondly, we studied the protective effects of MSC on white
matter injury. We showed that global HI induced a marked loss
of preOLs, which was paralleled by hypomyelination of the
preterm brain. In line with clinical evidence [37], FA values
obtained with diffusion tensor imaging (DTI) were decreased
following global HI indicating HI-induced breakdown of white
matter organization. Intravenous administration of MSC
prevented the loss of preOLs after global HI and reduced
histological white matter injury, which was confirmed with DTI.
The third step was to study neuronal injury on a functional level
by assessing electrographic seizure burden following global HI
in amplitude-integrated electroencephalogram (aEEG). Our
findings showed that intravenous MSC treatment decreased
the electrographic seizure activity following global HI. Reducing
seizure activity is clinically highly relevant, since several
studies have shown that seizures in neonatal HIE are
associated with adverse neurodevelopmental outcome [38–40].
The preceding findings showed that intravenous MSC
reduced the initial inflammatory response in the preterm brain
mediated by microglia and provided protection against evolving
white matter and neuronal injury after global HI. To further
assess the mechanism underlying the therapeutic effects of
MSCs, we studied modulation of the peripheral T-cell response
and subsequent invasion of these cells into the ischemic
Figure 7.  MSC were detected in the fetal ovine brain.  A FISH probe specific for the human Y-chromosome detected the
presence of systemically delivered MSC in the ovine brain. (A–D) Representative fluorescent images of the SCWM in the different
experimental groups; (A) sham-SAL, (B) sham-MSC, (C) HI-SAL and (D) HI-MSC. (A–B) In saline treated animals the FISH probe
did not react with any nucleus. (C–D) The FISH probe was detected in MSC treated animals indicating that MSC were present in the
preterm brain 7 d after intravenous administration. Scale bars: (A–D) 50 µm, scale bars inserts: (A–D) 5 µm.
doi: 10.1371/journal.pone.0073031.g007
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preterm brain. We and others have previously shown that the
initial cerebral inflammatory response after the hypoxic-
ischemic insult is followed by a second peripheral inflammatory
response characterized by mobilization and invasion of
peripheral immune effector cells (i.e. neutrophils and T-cells)
into the preterm brain [10,11,36,41]. Previous in vitro studies
have demonstrated that MSC suppressed helper T-cell
proliferation and induced an anti-inflammatory, more tolerant,
phenotype in these immune effector cells [42–44]. These
findings were confirmed and extended by our study showing
that MSC induced persistent tolerance of T-cells in vivo.
Furthermore, we showed that the degree of peripheral T-cell
tolerance was inversely related to cerebral inflammation.
Moreover we found that MSC reduced T-cell invasion following
global HI. Based on these findings, we hypothesize that
sequestered MSC modulated peripheral helper T-cells to
become unresponsive, making them less susceptible for
activation and mobilization in response to brain-derived
damage signals following global HI. This suppression of
peripheral immune cells may decrease invasion of immune
effector cells into the brain observed after global HI, thereby
reducing a second inflammatory hit to the ischemic preterm
brain [11].
The newly identified modulation of T-cell tolerance in vivo
and reduction of T-cell invasion after intravenous MSC
administration adds to the understanding of the anti-
inflammatory effects of MSC in the context of inflammation-
driven organ injury. Besides the anti-inflammatory effects of
MSC in our model, we speculate that the observed protective
effects of MSC on white matter injury are based on additional
mechanisms. First, the MSC-mediated reduction of cerebral
inflammation potentially reduced injury to vulnerable preOLs in
the preterm brain. This concept is supported by studies
showing microglia-mediated injury to preOLs [45] and our
findings that preOL density and myelination in the subcortical
white matter were inversely related to proliferation of microglia.
A second effect might be attributed to MSC-mediated
regeneration of lost preOLs and diminished arrested
oligodendrocyte maturation. The latter concept is supported by
in vitro data showing that MSC stimulate neural progenitor cells
to differentiate towards the oligodendrocyte lineage [46,47] and
in vivo data demonstrating remyelination after intracerebral
delivery of MSC in a rat model of neonatal hypoxic-ischemic
brain injury [48].
From the MSC that were administered intravenously, only a
few cells (<0.01%) were located within the preterm ovine brain
at seven days after global HI. PCR and sequencing confirmed
the presence of MSC in the brain and also confirmed that MSC
were present in lung and spleen seven days after intravenous
administration. In concordance with our findings, a study by
Lee et al. showed that MSC were neuroprotective in a rat
model of neonatal hypoxic-ischemic brain injury, while less
than 0.01% of intravenously administered MSC were recovered
in brain, lung and spleen tissue within 96 h after infusion [49].
Remarkably, also intracerebral injected MSC were shown to be
neuroprotective, although they disappeared rapidly after
injection [50]. These findings suggest that the neuroprotective
effects of MSC last longer than their presence implying that
MSC-mediated modulation of inflammation and repair of injury
is initiated early after administration.
Several other studies using rodent models of neonatal
hypoxic-ischemic brain injury have previously shown
neuroprotective effects of MSC after intracerebral injection
[18,20,48], intranasal [51] and intravenous administration
[17,21]. These rodent models however have several limitations
that make them less suitable for clinical translation [23,24,52].
The strength of the instrumented preterm sheep model is that it
closely resembles human preterm neurodevelopment and
second, that the global HI insult induced by umbilical cord
occlusion accurately mimics the common clinical etiology of
HIE in preterm infants [24,52].
We showed that xenotransplanted human MSC effectively
modulated immune responses and stimulated neuronal repair
in preterm sheep, without any signs of immunological rejection.
These findings are in line with early work by Zanjani et al.
showing that human xenotransplanted HSC were well tolerated
by the permissive environment of preimmune fetal sheep [53]
and even after establishment of the fetal immune system [32].
The latter findings indicated that MSC have unique
immunological characteristics that allow them to persist in a
xenogeneic environment [32].
The observed neuroprotective effects in our model were
seen following severe hypoxic-ischemic brain injury suggesting
that the MSC-mediated treatment effects will be enhanced
following milder episodes of ischemia in the preterm brain.
Although the dosage of MSC administered in our model was
consistent with completed [21,54] and ongoing
(ClinicalTrials.gov: NCT01501773, NCT01297413,
NCT01678534) clinical trials of focal cerebral ischemia (i.e.
stroke), dose escalation studies need to be conducted to
determine the optimal dosing strategy in hypoxic-ischemic
preterm brain injury. In addition, the magnitude of the treatment
effect may depend on the timing of intervention; we infused
MSC 1 h after the HI insult particularly aimed at intervening
early with the detrimental inflammatory response following
global HI. However, it is conceivable that repetitive dosing may
especially enhance the regenerative effects of MSC.
Furthermore, neuroprotective effects of MSC observed here
may have been underestimated after a reperfusion period of
one week. It is plausible that additional MSC-mediated repair of
white matter and neuronal networks takes place beyond the
period of one week after global HI. Whether the observed
structural changes and reduction in electrographic seizures are
associated with long term improvement of cognitive and
motoric function needs to be addressed in future (clinical)
studies [13].
In conclusion, we report for the first time that intravenously
administered mesenchymal stem cells (MSC) were
neuroprotective in a translational ovine model of preterm brain
injury after global HI. We demonstrated that MSC protected the
preterm brain against white matter injury and established
functional improvement. We provide evidence that the
neuroprotective effects of MSC may be mediated by
modulation of the peripheral T-cell response after global HI.
Further experimental research is needed to elucidate the anti-
inflammatory and regenerative mechanisms of action of MSC
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and to evaluate the long-term therapeutic effect of MSC on
motoric and cognitive function after global HI. Future clinical
trials should focus on the optimization of timing and dosing of
MSC therapy in preterm infants with hypoxic-ischemic brain
injury.
Supporting Information
Figure S1.  Gating strategy proliferation assay.
(A–C) Dot plots illustrating gating strategy in the flow cytometry
analysis of the proliferation assay. FSC = forward scatter, SSC
= sideward scatter, 7-AAD = 7-Aminoactinomycin D (viability
stain).
(TIF)
Figure S2.  Correlation plots.
(A) Density of immature preOLs was inversely related (Pearson
r = -.83, P<0.001) to IBA-1 immunoreactivity in the SCWM. (B)
MBP immunoreactivity was inversely related (Pearson r = -.71,
P=0.002) to IBA-1 immunoreactivity in the SCWM. (C) The
number of non-proliferating CD4-positive T cells harvested
from the spleen was inversely related (Pearson r = -.60,
P=0.035) to IBA-1 immunoreactivity in the subcortical white
matter.
(TIF)
Figure S3.  Detection of human specific β-2-microglobulin
DNA sequences in preterm sheep brain.
Genomic DNA was extracted from subcortical white matter of a
MSC treated animal (MSC) and a saline treated animal (SAL)
and analyzed by nested PCR for the presence of human β-2-
microglobulin (B2M) DNA sequences. The presence of
amplifiable DNA was evaluated by PCR for β-actin (actin). - =
water control, + = positive control; genomic DNA extracted from
one million human MSC.
(TIF)
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